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Introduction
The regulation of chemicals identifies specific 
classes of health hazards such as carcinogens, 
mutagens, and reprotoxicants. Endocrine 
disruptors (EDs) are a newer type of hazard 
identified by research. The World Health 
Organization (WHO) defined an ED as “an 
exogenous substance or mixture that alters 
the function(s) of the endocrine system and 
consequently causes adverse effects in an 
intact organism, or its progeny, or (sub)popu-
lations” (WHO/IPCS 2002). Following the 
first scientific reference to EDs (Colborn et al. 
1993), a large body of research has consider-
ably improved our understanding of their 
effects in wildlife and humans (e.g., Bergman 
et al. 2013; Braun et al. 2011; Delfosse et al. 
2014; Frye et al. 2012; Heindel et al. 2015; 
Kortenkamp et al. 2011; Shelton et al. 2014; 
Warner et al. 2014; Woodruff et al. 2011).
In 1999, the European Union (EU) 
became the first major economy to develop a 
strategy for the regulation of EDs (European 
Commission 1999). Subsequently, EDs have 
been addressed in at least four acts of EU 
law: the water framework directive (European 
Parliament 2000), REACH (the European 
Regulation on Registration, Evaluation, 
Authorisation and Restriction of Chemicals) 
(European Parliament 2006), the Plant 
Protection Products Regulation (PPPR) 
(European Parliament 2009a), the Cosmetics 
Regulation (European Parliament 2009b), 
as well as the Biocidal Products Regulation 
(BPR) (European Parliament 2012). The 
two latter regulations required the European 
Commission to establish scientific criteria to 
identify substances with endocrine-disrupting 
properties before December 2013.
The PPPR and the BPR specify that 
substances with ED properties used as pesti-
cides or biocides will not receive approval 
for their use, with certain exceptions (e.g., 
if exposure is negligible, for the PPPR). 
Similar provisions exist for carcinogens, 
mutagens, and reprotoxicants. Thus, these 
laws are not based on risk assessment for EDs 
present in biocides and pesticides, but only 
require hazard identification if exposure is 
not negligible. This corresponds to so-called 
“hazard-based cut-off criteria” (see Figure 1 
for the distinction between hazard—a source 
of potential health effects—and risk—the 
actual impact of a substance in a population, 
in terms of disease probability or number of 
attributable disease cases). This hazard-based 
approach to pesticide and biocide regula-
tion has been opposed by companies that 
market pesticides and biocides (CEFIC 2013; 
European Commission 2015; European Crop 
Protection Association 2014).
In addition, editors of pharmacology 
and toxicology journals condemned in an 
editorial the proposed European Commission 
recommendations on ED regulations, which 
they claimed were based on scientifically 
unfounded precaution and defied common 
sense and well-established risk assessment 
principles; the editors called for the consider-
ation of adverse effects and potency (Dietrich 
et al. 2013). Their editorial was criticized for 
being based on a factually incorrect interpre-
tation of the proposed regulatory framework 
and for ignoring the programming role of 
the endocrine system during development 
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Background: Endocrine disruptors (EDs) are defined by the World Health Organization (WHO) 
as exogenous compounds or mixtures that alter function(s) of the endocrine system and conse-
quently cause adverse effects in an intact organism, or its progeny, or (sub)populations. European 
regulations on pesticides, biocides, cosmetics, and industrial chemicals require the European 
Commission to establish scientific criteria to define EDs.
oBjectives: We address the scientific relevance of four options for the identification of EDs 
proposed by the European Commission.
discussion: Option 1, which does not define EDs and leads to using interim criteria unrelated to 
the WHO definition of EDs, is not relevant. Options 2 and 3 rely on the WHO definition of EDs, 
which is widely accepted by the scientific community, with option 3 introducing additional catego-
ries based on the strength of evidence (suspected EDs and endocrine-active substances). Option 4 
adds potency to the WHO definition, as a decision criterion. We argue that potency is dependent 
on the adverse effect considered and is scientifically ambiguous, and note that potency is not used 
as a criterion to define other particularly hazardous substances such as carcinogens and reproductive 
toxicants. The use of potency requires a context that goes beyond hazard identification and corre-
sponds to risk characterization, in which potency (or, more relevantly, the dose–response function) 
is combined with exposure levels.
conclusions: There is scientific agreement regarding the adequacy of the WHO definition of 
EDs. The potency concept is not relevant to the identification of particularly serious hazards such 
as EDs. As is common practice for carcinogens, mutagens, and reproductive toxicants, a multi-level 
classification of ED based on the WHO definition, and not considering potency, would be relevant 
(corresponding to option 3 proposed by the European Commission).
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substances in the European Union. Environ Health Perspect 124:1497–1503; http://dx.doi.
org/10.1289/EHP217
Slama et al.
1498 volume 124 | number 10 | October 2016 • Environmental Health Perspectives
(Bergman et al. 2013; Gore et al. 2013).
Its authors were also called upon to provide 
information about potential conflicts of 
interest (Grandjean and Ozonoff 2013).
At a meeting convened by the EU 
Commission including signatories of the 
Dietrich et al. (2013) editorial and scien-
tists with a strong base in ED research, 
a consensus was reached on the definition 
of EDs, on the existence of nonmonotonic 
dose responses, and on the difficulties of 
determining thresholds for EDs (European 
Commission 2013).
Despite the obligations to establish scien-
tific criteria to identify EDs by December 
2013, as specified by EU laws (European 
Parliament 2009a, 2012), no such criteria 
have been published to date (April 2016) 
by the European Commission. Instead, the 
European Commission published a roadmap 
listing four options for defining criteria for 
identifying EDs and initiated an assessment 
of their impact (European Commission 2014) 
(Table 1). One of the options included in 
the roadmap (option 4) would use potency 
as a decision criterion during the process of 
hazard identification.
The disregard for the obligations laid 
down in EU law led Sweden and several 
other EU countries to sue the European 
Commission. In December 2015, the 
European Court of Justice ruled that the 
European Commission acted unlawfully in 
failing to develop ED criteria and that an 
impact assessment was unnecessary (European 
Court of Justice 2015). This judgment height-
ened the urgency of developing scientifically-
based regulatory criteria for identifying EDs.
We elaborate some principles of ED regu-
lation and specifically discuss the scientific 
relevance of each option considered by the 
European Commission to identify an ED, 
reviewing the availability of accepted defini-
tions of EDs, endocrine-active substances, 
and the relevance of the concept of potency 
for hazard identification. A parallel with 
carcinogens is drawn. The relevance of impact 
assessment studies to define scientific criteria 
is finally discussed.
Discussion
Proposed Options Regarding 
Criteria for EDs in Europe
The general intention of defining ED criteria 
is “to ensure a high level of protection to 
human health and the environment and to 
strengthen the functioning of the internal 
market” (European Commission 2014). 
The four options proposed (European 
Commission 2014) are detailed in Table 1 
and summarized below:
• Option 1 consists of no policy change and 
no specification of criteria.
• Option 2 relies on the WHO definition 
to identify EDs (WHO/IPCS 2002). This 
option a) identifies EDs as substances 
known or presumed to cause endocrine-
mediated adverse effects in humans or 
animal species living in the environment; 
b) stipulates that endocrine-mediated 
adverse effects should not be a nonspe-
cific secondary consequence of other toxic 
effects; c) defines “adverse effects” (as 
discussed below); d) excludes substances 
for which there is information demon-
strating that the effects are not relevant 
for humans and for animal species living 
in the environment; and finally e) lists the 
step-by-step procedure to be followed for 
the identification.
• Option 3 relies on the identification of 
ED as in Option 2 and further defines 
“suspected endocrine disruptors” and 
“endocrine active substances” (see below).
• Option 4 relies on the WHO/IPCS defini-
tion of ED, and includes “potency” as an 
element of hazard characterization. Potency 
is not defined, nor is the manner in which it 
would be combined with the ED definition.
The European Commission (2014) 
indicated that Option 1 (no specification of 
criteria) would run counter to the require-
ments of regulations calling for an operational 
definition of EDs. Moreover, the PPPR 
and BPR laws mention interim criteria, 
and these would likely apply. According to 
these interim criteria, all substances classi-
fied as carcinogenic category 2 and toxic for 
reproduction category 2 shall be considered 
as EDs (European Parliament 2009a). These 
interim criteria based on the definitions of 
carcinogens and reproductive toxicants have 
no scientific relevance to the WHO/IPCS 
definition of endocrine disruptors (WHO/
IPCS 2002), so Option 1 would not be 
scientifically justified. Consequently, we do 
not discuss this option further.
Availability of a Definition of EDs
Option 2 of the roadmap defines EDs and 
adverse effect. At a workshop convened in 
1996 in Weybridge (UK) by the European 
Commission, WHO and other institu-
tions, an ED was defined as “an exogenous 
substance that causes adverse health effects in 
an intact organism, or its progeny, secondary 
to changes in endocrine function” (quoted by 
EFSA Scientific Committee 2013). Several 
definitions were subsequently suggested by 
Canadian, Japanese, and other institutions 
(reviewed by Kortenkamp et al. 2011), 
after which the International Program on 
Chemical Safety (IPCS), in collaboration 
with experts from Canada, Japan, the United 
States, and the EU, defined an ED as “an 
exogenous substance or mixture that alters 
the function(s) of the endocrine system 
and consequently causes adverse effects in 
an intact organism, or its progeny, or (sub)
populations” (WHO/IPCS 2002). The main 
differences from the Weybridge definition are 
the consideration of mixtures and of effects in 
populations or subpopulations.
The definition issued from the workshop 
convened by the U.S. Environmental 
Protection Agency (EPA) in 1995 in Raleigh, 
North Carolina (Kavlock et al. 1996), which 
is still referred to by the U.S. EPA (2015), 
differs from the WHO/IPCS definition 
by lack of reference to adverse effects. As 
discussed below, substances acting on the 
endocrine system without evidence of an 
adverse health effect would be defined as 
endocrine-active substances under Option 3.
For other categories of health hazards, 
specific adverse health effects are often 
referred to, as is the case for carcinogens or 
Figure 1. Hazard-based versus risk-based management of hazards. The step of risk characterization is 
sometimes (ambiguously) termed hazard characterization.
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reprotoxins, whereas for mutagens there 
is only a reference to a mode of action. The 
WHO/IPCS definition of EDs refers to both 
a mode of action and an adverse effect at the 
scale of organs, organisms, or populations. 
Consequently, conclusions about the nature 
of an ED require the integration of biochem-
ical, toxicological, and ecotoxicological/
human data.
EFSA (European Food Safety Authority) 
recommended that the WHO/IPCS defini-
tion be “adopted as a basis for the criteria for 
the identification of EDs” (EFSA Scientific 
Committee 2013). The European Commission 
roadmap acknowledges that “there is general 
consensus on the WHO/IPCS (2002) defini-
tion of an ED” (European Commission 2014).
The ED definition mentions “adverse 
effects.” Adverse effects were defined as a 
“change in the morphology, physiology, 
growth, development, reproduction or lifespan 
of an organism, system or (sub)population 
that results in an impairment of functional 
capacity, an impairment of the capacity to 
compensate for additional stress or an increase 
in susceptibility to other influences” (WHO/
IPCS 2009). The EC roadmap explicitly refers 
to this definition. This definition covers health 
effects at the individual level such as occur-
rence of diabetes or obesity, IQ loss, as well 
as congenital malformations, or changes not 
visible at the individual but only at the popu-
lation level, such as alteration of the sex ratio. 
It excludes, among others, transient changes 
in hormone levels that would not induce 
health effects in the short or long term. To our 
knowledge, this definition has not been ques-
tioned. The expression of “(sub)population” 
in WHO/IPCS definition refers to effects that 
may concern the population as a whole or 
a specific subgroup (e.g., based on sex, age, 
genetic susceptibility).
Suspected EDs and Endocrine 
Active Substances (Option 3)
In addition to defining an ED as in Option 2, 
Option 3 proposes two additional catego-
ries, suspected endocrine disruptors and 
endocrine-active substances, that express the 
strength of evidence for a given compound.
“Suspected endocrine disruptors” are 
defined in the roadmap as “Substances where 
there is some evidence for endocrine-mediated 
adverse effects from humans, animal species 
living in the environment or from experi-
mental studies, but where the evidence is not 
sufficiently strong to place the substance in 
Category I” (European Commission 2014). 
This definition is close to the WHO/IPCS 
definition of a “possible endocrine disruptor” 
(“an exogenous substance or mixture that 
possesses properties that might be expected 
to lead to endocrine disruption in an intact 
organism, or its progeny, or (sub)populations”) 
Table 1. Four options to identify endocrine-disrupting substances in the EC 2014 roadmap (European Commission 2014).
Option Details Comments
1 No criteria are specified. The interim criteria set in the BPR and PPPR continue to apply. Would run counter to the PPPR and BPR, which require 
scientific criteria to be defined. Would lead to the interim 
criteria [which are not coherent with the WHO/IPCS 
(2002) definition of EDs] to be used.
2 WHO/IPCS definition (WHO/IPCS 2002) to identify ED (hazard identification). ED are identified as:
a) Substances that are i) known or presumed to have caused endocrine-mediated adverse effects in 
humans or population-relevant endocrine-mediated adverse effects in animal species living in the 
environment or ii) where there is evidence from experimental studies (in vivo), possibly supported with 
other information (e.g., QSAR, analogue, and category approaches) to provide a strong presumption 
that the substance has the capacity to cause endocrine-mediated adverse effects in humans or 
population-relevant endocrine-mediated adverse effects on animal species living in the environment;
b) The experimental studies used to determine if a substance is an endocrine disruptor shall provide clear 
evidence of endocrine-mediated adverse effects in the absence of other toxic effects, or, if occurring 
together with other toxic effects, the endocrine-mediated adverse effects should not be a nonspecific 
secondary consequence of other toxic effects;
c) An adverse effect is a change in the morphology, physiology, growth, development, reproduction, or life 
span of an organism, system, or (sub)population that results in an impairment of functional capacity, 
an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to 
other influences, as stated by WHO/IPCS (2009);
d) where there is (e.g., mechanistic) information demonstrating that the effects are clearly not relevant 
for humans and not relevant at population level to animal species living in the environment, then the 
substance should not be considered an endocrine disruptor;
e) The identification shall follow a step-by-step procedure as follows: i) gather all available data; ii) assess 
the data quality, reliability, reproducibility, and consistency; iii) consider adversity and mode of action 
together in a weight-of-evidence approach based on expert judgment; iv) evaluate whether endocrine 
disruption is attributable to a specific endocrine-mediated mode of action and not to a nonspecific 
secondary consequence of other toxic effects; v) evaluate human and wildlife relevance; vi) final (eco)
toxicological evaluation indicating, where possible, whether the adverse effect is in relation to human 
health or environment (vertebrates and/or invertebrate populations), and where possible which are the 
axes or mechanisms concerned (e.g., estrogenic, androgenic, thyroid, and/or steroidogenic axes). 
3 WHO/IPCS (2002) definition to identify ED (hazard identification) as in Option 2. Introduction of additional 
categories based on the different strength of evidence for fulfilling the WHO/IPCS definition:
Category I: “endocrine disruptors” (as defined in 2a–2d).
Category II: “suspected endocrine disruptors,” defined as substances where there is some evidence 
for endocrine-mediated adverse effects from humans, animal species living in the environment, or 
experimental studies, but where the evidence is not sufficiently strong to place the substance in Category I. 
If, for example, limitations in the studies make the quality of evidence less convincing, Category II could be 
more appropriate. Points 2b, 2c (definition of adverse effect), and 2d above remain valid for Category II.
Category III: “endocrine-active substances,” defined as substances for which there is some in vitro 
or in vivo evidence indicating a potential for endocrine disruption–mediated adverse effects in intact 
organisms and where the evidence is not sufficiently convincing to place the substance in Category I or II.
The allocation to categories shall follow a step-by-step procedure (identical to that listed in 2e above).
The definition of “endocrine-active substances” 
(Category III) does not follow the definition provided by 
EFSA, which refers to substances that can interfere or 
react with the endocrine system (without evidence of 
adverse effect).
4 WHO/IPCS definition (WHO/IPCS 2002) to identify ED (hazard identification) and inclusion of potency as 
element of hazard characterization.
Potency is not defined. Option 4 introduces elements of 
risk assessment. No step-by-step procedure provided as 
in 2 and 3.
Abbreviations: BPR, Biocide Products Regulation (EU); PPPR, Plant Protection Products Regulation (EU); QSAR, quantitative structure–activity relationship.
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(WHO/IPCS 2002). “Endocrine-active 
substances” are defined in the European 
Commission roadmap as “Substances for which 
there is some … potential for endocrine disrup-
tion mediated adverse effects in intact organ-
isms and where the evidence is not sufficiently 
convincing to place the substance in category I 
[ED] or II [suspected ED]” (European 
Commission 2014). We believe that the termi-
nology of “endocrine-active substance” does 
not convey this lower level of evidence (a hier-
archy such as ED [category I], presumed ED 
and suspected ED, similar to that of carcino-
gens shown in Table 2, would better fit this 
purpose). In contrast, an “ endocrine- active 
substance” is defined by EFSA as “any chemical 
that can interact directly or indirectly with the 
endocrine system, and subsequently result in 
an effect on the endocrine system, target organs 
and tissues” (EFSA Scientific Committee 
2013). The term is used to cover “all substances 
that in some way interfere with the endocrine 
system, but need not necessarily induce adverse 
effects.” This definition transmits the notion 
that there is evidence regarding the mode of 
action of the substance (interference with the 
endocrine system), but not regarding the induc-
tion of adverse effects, which is in line with the 
terminology of endocrine-active substances. 
Therefore, we suggest using the EFSA defini-
tion for endocrine-active substances instead of 
the EC roadmap definition.
Introduction of Potency as a 
Criterion for Hazard Identification 
(Option 4)
Option 4 of the roadmap is based on the 
WHO/IPCS definition of an ED, with 
potency as an added criterion. This option 
echoes approaches developed by the United 
Kingdom and German authorities with the 
explicit intention of limiting the number of 
substances that would fall under the hazard-
based cut-off criteria of the PPPR and BPR 
(discussed by Kortenkamp et al. 2011). A 
publication from the German federal institute 
for risk assessment also suggested to consider 
potency to identify EDs (Marx-Stoelting 
et al. 2015).
Potency is not well defined; it is not in 
the glossary of terms of the environmental 
health criteria published by the International 
Program on Chemical Safety (IPCS 2009). 
The term is presented in a publication spon-
sored by ECETOC—the European Centre for 
Ecotoxicology and Toxicology of Chemicals, 
a nonprofit association of companies with 
interests in the manufacture and use of 
chemicals—as being “primarily based on the 
dose causing a specific toxic effect” without 
being clearly defined (Hennes et al. 2014). A 
publication from the German federal insti-
tute for risk assessment indicates that “Potency 
relates to the dose levels at which certain 
effects occur” (Marx-Stoelting et al. 2015). 
The International Union of Pharmacology 
defines potency as “an expression of the activity 
of a drug, in terms of the concentration or 
amount needed to produce a defined effect; an 
imprecise term that should always be further 
defined (see EC50, IC50, etc.),” where EC50 
is further defined as “The molar concentra-
tion of an agonist that produces 50% of the 
maximal possible effect of that agonist. Other 
percentage values (EC20, EC40, etc.) can be 
specified” (Neubig et al. 2003).
Hence, in pharmacology, potency is 
related to the dose–response function: A 
substance that at a certain dose causes 50% 
of its possible maximal effect magnitude 
(e.g., rate of animals with a specific disease) 
is considered more potent than another 
substance for which the same effect magni-
tude is attained at a larger dose. As already 
mentioned (Neubig et al. 2003), sometimes 
doses other than those leading to 50% of 
a given effect are used, such as 10% of a 
given effect, without apparent scientific 
justification of how these cut-off values are 
chosen. Thus, potency is simply a point of 
the dose–response function, corresponding 
to the dose at which this dose–response 
function intersects an arbitrary response level 
(Figure 2A).
The step-by-step procedure of the EC 
roadmap (Options 2 and 3) mentions that 
it is necessary to evaluate whether endo-
crine disruption is attributable to a specific 
endocrine-mediated mode of action and not 
to a nonspecific secondary consequence of 
other toxic effects (European Commission 
2014). Consequently, effects that would 
occur at very high doses at which general 
toxicity is observed would not be enough to 
qualify the compound as an ED, without the 
need to explicitly introduce concepts related 
to the dose at which effects occur.
The introduction of potency as a crite-
rion in hazard identification would lead to 
several difficulties. First, this concept is not 
suited for compounds for which nonmono-
tonic dose–response functions are possible, 
as is the case for EDs (Vandenberg et al. 
2012). Second, the introduction of potency 
as a decision criterion may force the estab-
lishment of dichotomous regulatory cut-off 
values that are entirely arbitrary and not 
science-based, such that a compound with 
a potency of 10 mg/kg/day might be classi-
fied as an ED, while a compound with a 
potency of 11 mg/kg/day (hence causing the 
same effect at an exposure of 11 instead of 
10 mg/kg/day) would not be classified as an 
ED. Third, potency comparisons are influ-
enced by the effect magnitude that is chosen to 
define the doses to be compared (i.e., whether 
one considers a 10% or a 50% increase; see 
Figure 2A) and by the health end point consid-
ered to define potency. Overall, potency is not 
a relevant concept for hazard identification.
Even in the context of risk management, 
potency alone is of little use. Indeed, dose–
response functions, from which potency is 
defined, are not meaningful alone and need 
to be interpreted in relation to exposure, 
Figure 2. Illustration of issues with the potency concept, with hypothetical dose–response functions and distributions of exposure. (A) Situation of dose–response 
functions that cross: If potency is defined as the dose ED50 leading to 50% of a given response, then chemical with the dose–response function a is considered 
more potent than chemical with exposure–response function b; if potency is defined as the dose leading to 10% of the response (ED10), then chemical with dose–
response function a is less potent than chemical with dose–response function b. (B) Shallow dose–response function (and low potency) with a large proportion 
of highly exposed subjects, hence entailing a possibly high risk. (C) Steep dose–response function (and high potency) with a low proportion of highly exposed 
subjects, hence entailing a possibly similar or lower risk. Blue bars in B and C represent the distribution of exposure in the population.
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which allows estimation of the level of risk for 
a given population (Figure 1). Low potency 
compounds with shallow dose–response func-
tions and very frequent exposures (Figure 2B) 
may present greater risks at the population 
level than more potent chemicals with steep 
dose–response functions but less frequent 
exposure (Figure 2C). Well-established 
examples illustrating that the dose response 
(or potency) cannot be considered alone to 
predict risk include airborne fine particulate 
matter (≤ 2.5 μm; PM2.5) (WHO 2014) and 
low exposures during critical windows of 
vulnerability like fetal development, such as 
those demonstrated for effects of PCBs on 
intellectual quotient (Jacobson and Jacobson 
1996; Schantz et al. 2003). Accordingly, the 
EFSA scientific committee stated “that, to 
assess whether or not a (predefined) level of 
concern is reached for an ED, potency should 
not be used alone but should take account of 
actual or predicted exposure” (EFSA Scientific 
Committee 2013). Indeed, potency replaces 
dose–response curves by a single point of the 
curve, which results in a strong loss of infor-
mation. If a risk-based and not hazard-based 
management is chosen, the relevant approach 
is to take into account the variations of the 
dose–response function over the whole range 
of exposures and combine it with actual 
exposures, for all relevant health outcomes, in 
other words to explicitly perform a risk assess-
ment study—but this goes beyond the steps 
required for hazard identification.
In the context of the PPPR, where some 
substances are to be regulated mostly on 
the basis of their hazard (at least if exposure 
is not negligible) and not their risk, consid-
ering dose–response functions (or potency) at 
the step of hazard identification would lead 
to reintroducing a logic of risk assessment. 
The discussion of whether or not the hazard-
based logic of the PPPR and BPR for EDs 
should be modified into a risk-based regula-
tion is a matter of policy. If deemed relevant 
by regulators, risk assessment should not be 
reintroduced partially (by considering only a 
component of risk assessment), nor “by the 
back door,” indirectly, by requiring consid-
eration of a criterion related to risk assess-
ment such as potency. Rather, if necessary, 
this should be done explicitly, by modifying 
the legislation.
Parallel with Hazard Identification 
in the Field of Carcinogens
Another key argument against adopting 
criteria considering potency is consistency 
with the identification of other hazards 
of similar concern, such as carcinogens or 
reproductive toxicants. Several other types 
of chemical hazards are explicitly referred 
to in the EU regulation, including carcino-
gens, mutagens, reprotoxins. Carcinogens 
are defined as “a substance or a mixture of 
substances which induce cancer or increase 
its incidence. Substances which have 
induced benign and malignant tumors in 
well-performed experimental studies on 
animals are considered also to be presumed 
or suspected human carcinogens unless there 
is strong evidence that the mechanism of 
tumor formation is not relevant for humans” 
(European Parliament 2008). For carcino-
gens, the EU defines three categories for 
carcinogenic substances (Ia, Ib, and II, the 
last corresponding to suspected carcinogens, 
Table 2). The classification of a substance in 
any category is based on a scientific assessment 
of the hazard (hazard identification) and does 
not take into consideration other components 
of the risk assessment scheme (Figure 1) such 
as “potency.” Opting for options 2 or 4 would 
separate EDs from other hazards of equivalent 
concerns because the number of hazard cate-
gories would differ (in the case of Option 2, 
for which a substance is either identified as an 
ED or not, not alerting industry, consumers 
or policy makers to suspected EDs) or because 
potency would be considered (Option 4). 
This would run counter to the policy choice 
of the legislation to consider EDs as being of 
equivalent concern to carcinogens, mutagens, 
and reprotoxicants. Overall, the example of 
carcinogens shows that criteria defining a 
serious hazard need not be complex, nor need 
to resort to potency and risk-related concepts.
Impact Assessment Studies Are 
Not Designed to Help Defining 
Hazards
The European Commission is carrying out 
an impact assessment as a preliminary step 
before deciding among the four options. 
Impact assessment studies provide an assess-
ment of the potential economic, social and 
environmental impacts of alternative policy 
options. They would make sense if policy 
options were currently examined (e.g., 
between hazard-based regulation of pesti-
cides or risk-based regulation), or after the 
implementation of a policy to judge its results. 
Here the relevant regulations (PPPR, BPR, 
REACH laws) have already been enacted but 
not applied as far as EDs are concerned.
Scientific criteria should rely on a scien-
tific foundation. It is not the evaluation of 
the impact of a family of compounds that 
should guide their scientific definition; rather, 
the adoption of a scientific definition condi-
tions any impact evaluation. Continuing the 
previous parallel with other health hazards, 
carcinogens were defined before obtaining 
a clear picture of the number of existing 
carcinogens, and independently of their 
impact. Similarly, it would not be necessary 
to perform an impact assessment study before 
defining X-rays or explosives.
Studies of the impact of some EDs on 
disease burden and cost in Europe have 
already been published (Trasande et al. 
2015). The economic cost associated with 
exposure to non-banned EDs in the EU was 
estimated to be 157 billion euros per year 
(Trasande et al. 2015).
If option A leads to the identification of 
10 substances that are EDs while option B 
identifies 50 further substances, will option B 
be preferred to limit the health impact of EDs 
or will option A be chosen to limit constraints 
on the industrial sector? Economic and health 
impacts are subject to quick changes as a 
function of exposure levels, development of 
substitutes or alternative industrial processes, 
and existence of companies with relevant 
substitutes. Will the impact assessment be 
updated to take these changes into account, 
and the criteria modified accordingly?
Table 2. Categories of carcinogenic substances, as defined by the EU CLP regulation (EC, No. 1272/2008 
on classification, labeling and packaging of substances and mixtures). 
Carcinogensa
Endocrine-disrupting chemicals  
(Option 3 of the EC roadmap)
Hazard class Hazard class
Category Ia Substances known to have carcinogenic 
potential for humansb
I Substances known or presumed 
to be an endocrine disruptor
Category Ib Substances presumed to have carcinogenic 
potential for humansb
II Suspected endocrine disruptors
Category II Suspected human carcinogensc III Endocrine-active substances
In the right-hand column, we have added the 3 levels for EDs proposed in Option 3 of the European Commission (2014) 
roadmap. 
aA carcinogen is defined as a substance or a mixture of substances which induce cancer or increase its incidence. 
Substances that have induced benign and malignant tumors in well-performed experimental studies on animals are 
considered also to be presumed or suspected human carcinogens unless there is strong evidence that the mechanism 
of tumor formation is not relevant for humans (European Parliament 2008). bA substance is classified in Category I 
for carcinogenicity on the basis of epidemiological and/or animal data. A substance may be further distinguished as 
Category IA, known to have carcinogenic potential for humans, classification largely based on human evidence, or 
Category IB, presumed to have carcinogenic potential for humans, classification largely based on animal evidence. 
cAccording to the EU regulation, the placing of a substance in Category II (suspected human carcinogens) is done on 
the basis of evidence obtained from human and/or animal studies, but which is not sufficiently convincing to place 
the substance in Category IA or IB, based on strength of evidence together with additional considerations. Such 
evidence may be derived either from limited evidence of carcinogenicity in human studies or from limited evidence of 
 carcinogenicity in animal studies.
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In its ruling against the European 
Commission, the European court of justice 
stated that “the definition of scientific criteria 
to identify properties disrupting the endo-
crine system can only be done in an objective 
manner based on scientific data relative to the 
endocrine system, independently from any 
other consideration, and in particular from any 
economic consideration” (European Court of 
Justice 2015). Making a scientific definition 
dependent on the results of an assessment of 
its impact would be a dangerous precedent for 
public health and science in general.
Conclusion
The laws passed by the European parlia-
ment during the last decade constitute an 
innovative approach to limit health risks 
posed by EDs.
We have presented and discussed each 
option proposed by the European Commission 
to identify EDs (European Commission 
2014), and provided specific recommendations 
(Table 3). Only Options 2 and 3 comply with 
science. There is scientific consensus on the 
relevance of the WHO/IPCS definition of an 
ED (WHO/IPCS 2002). Option 4 modifies 
this definition by introducing the notion of 
potency, which is absent from the WHO/
IPCS definition and from the criteria identi-
fying carcinogens, which are hazards of equiva-
lent concern to EDs. We believe that, because 
of the parallel with definitions of carcinogenic 
hazards (which have different categories based 
on evidence levels) and because it calls for the 
identification of suspected EDs, Option 3 is 
more relevant. This will provide a simple clas-
sification conveying the weight of the scien-
tific evidence regarding the likelihood for the 
compound to be an ED: endocrine disruptors 
(including substances known or presumed to 
be EDs), suspected endocrine disruptors, and 
endocrine-active substances (Table 2).
We recognize that scientific uncertainty 
remains with regard to the finer detail of mech-
anisms, the exact extent of health and environ-
mental effects of EDs, and their impact at the 
population level. There are also great uncertain-
ties as to the number of substances likely to be 
identified as EDs. However, as demonstrated 
by the 40 years of work by the International 
Agency for Research on Cancer to identify 
carcinogens (Pearce et al. 2015), the availability 
of a clear definition of the hazard considered is 
a necessary first step. Once defining criteria are 
available, one can develop appropriate testing 
methods, identify substances, and manage risk. 
Some of the test methods that will be required 
for regulatory purposes need to be developed 
and agreed upon.
There is no scientific or public health 
justification for the delay in the adoption of 
scientific criteria for EDs.
As scientists, we believe that impact assess-
ment studies should not be used to define 
scientific criteria, nor be used as an argument 
for postponing the publication of a scientific 
definition. We are concerned that an impact 
assessment study could be used to bend 
science toward an outcome defined by aspects 
external to science. We are convinced that 
the (vague) notion of potency has no place 
in a hazard identification context. We are 
concerned that scientific definitions are being 
distorted in order to modify the spirit of a 
law that requires hazard-based management 
of EDs present in pesticides if exposure is not 
negligible, and not a risk-based management, 
thereby muddling science and policy. We 
believe that scientific criteria identifying EDs 
should follow the logic of the EU criteria for 
other serious hazards such as carcinogens and 
reproductive toxicants. We regret that several 
years have been spent trying to issue scien-
tific criteria defining a hazard that actually has 
been defined years earlier by a state-of-the-
science report from WHO. We fear that the 
most plausible explanation for this delay is not 
a lack of scientific consensus, but rather that 
postponing the publication of the scientific 
criteria is a way to postpone the full applica-
tion of the 2009 pesticide regulation and 2012 
biocide European regulation. This postpone-
ment is all the more worrying because these 
scientific criteria are but one of the first steps 
toward identifying EDs and providing more 
efficient protection of public health in the 
European Union.
Note added in proof: After acceptance of this 
manuscript, on 16 June 2016, the European 
Commission published proposals to define EDs in 
the context of the pesticides and biocides regula-
tions (European Commission 2016). The proposal 
suggested abandoning the hazard-based logic of 
management of pesticides containing EDs. See 
Kortenkamp et al. (2016) for a comment.
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